

Ezetimibe / Rosuvastatin Formulation

Version 3.0 Revision Date: 06.04.2024 SDS Number: 3177580-00014 Date of last issue: 30.09.2023
Date of first issue: 18.09.2018

Section 1: Identification

Product identifier : Ezetimibe / Rosuvastatin Formulation

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable


Manufacturer or supplier's details

Company : Organon & Co.
Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : +1-551-430-6000
Emergency telephone number : +1-215-631-6999
E-mail address : EHSSTEWARD@organon.com

Section 2: Hazard identification**Classification of the substance or mixture**

Carcinogenicity : Category 1B
Reproductive toxicity : Category 1B
Specific target organ toxicity - single exposure (Oral) : Category 2 (Liver, Kidney, muscle)
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Eye)
Long-term (chronic) aquatic hazard : Category 2

GHS Label elements, including precautionary statements

Hazard pictograms : 

Signal word : Danger

Hazard statements : H350 May cause cancer.
H360FD May damage fertility. May damage the unborn child.
H371 May cause damage to organs (Liver, Kidney, muscle) if

Ezetimibe / Rosuvastatin Formulation

Version 3.0 Revision Date: 06.04.2024 SDS Number: 3177580-00014 Date of last issue: 30.09.2023
Date of first issue: 18.09.2018

Precautionary statements	<p>swallowed. H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed. H411 Toxic to aquatic life with long lasting effects.</p> <p>Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.</p> <p>Response: P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor. P391 Collect spillage.</p> <p>Storage: P405 Store locked up.</p> <p>Disposal: P501 Dispose of contents/ container to an approved waste disposal plant.</p>
--------------------------	---

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 -< 20
Ezetimibe	163222-33-1	>= 2.5 -< 10
Rosuvastatin	147098-20-2	>= 2.5 -< 10
Sodium n-dodecyl sulfate	151-21-3	>= 1 -< 3
Magnesium stearate	557-04-0	>= 1 -< 10

Section 4: First-aid measures**Description of necessary first-aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed

Risks : May cause cancer.
May damage fertility. May damage the unborn child.
May cause damage to organs if swallowed.
May cause damage to organs through prolonged or repeated exposure if swallowed.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures**Extinguishing media**

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Fluorine compounds
Nitrogen oxides (NO_x)
Sulphur oxides
Metal oxides

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Special protective actions for fire-fighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Section 6: Accidental release measures**Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage**Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing. Do not breathe dust. Do not swallow.

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage, including any incompatibilities

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection**Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	PEL (long term)	10 mg/m ³	SG OEL
		TWA	10 mg/m ³	ACGIH
Ezetimibe	163222-33-1	TWA	25 µg/m ³ (OEB 3)	Internal
		Wipe limit	250 µg/100 cm ²	Internal
Rosuvastatin	147098-20-2	TWA	20 µg/m ³ (OEB 3)	Internal
		Wipe limit	200 µg/100 cm ²	Internal
Magnesium stearate	557-04-0	PEL (long term)	10 mg/m ³	SG OEL
		TWA (Inhal-)	10 mg/m ³	ACGIH

SAFETY DATA SHEET



Ezetimibe / Rosuvastatin Formulation



Version 3.0 Revision Date: 06.04.2024 SDS Number: 3177580-00014 Date of last issue: 30.09.2023
Date of first issue: 18.09.2018

		able particulate matter)		
		TWA (Respirable particulate matter)	3 mg/m3	ACGIH

Appropriate engineering control measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Individual protection measures, such as personal protective equipment (PPE)

- Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.

Section 9: Physical and chemical properties

- Appearance : powder
- Colour : white to off-white
- Odour : No data available
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available

SAFETY DATA SHEET



Ezetimibe / Rosuvastatin Formulation



Version 3.0 Revision Date: 06.04.2024 SDS Number: 3177580-00014 Date of last issue: 30.09.2023
Date of first issue: 18.09.2018

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics
Particle size : No data available

Section 10: Stability and reactivity

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:**Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

Ezetimibe:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg LD50 (Mouse): > 5,000 mg/kg LD50 (Dog): > 3,000 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 2,000 mg/kg Application Route: Intraperitoneal LD50 (Mouse): > 1,000 - < 2,000 mg/kg

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
3.0	06.04.2024	3177580-00014	30.09.2023
			Date of first issue: 18.09.2018

Application Route: Intraperitoneal

Rosuvastatin:

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg
		Target Organs: Liver, Stomach, muscle, Kidney

Sodium n-dodecyl sulfate:

Acute oral toxicity	:	LD50 (Rat): 1,200 mg/kg
		Method: OECD Test Guideline 401
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg
		Method: OECD Test Guideline 402
		Remarks: Based on data from similar materials

Magnesium stearate:

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg
		Method: OECD Test Guideline 423
		Assessment: The substance or mixture has no acute oral toxicity
		Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg
		Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Ezetimibe:**

Species	:	Rabbit
Result	:	No skin irritation

Sodium n-dodecyl sulfate:

Species	:	Rabbit
Result	:	Skin irritation

Magnesium stearate:

Species	:	Rabbit
Result	:	No skin irritation
Remarks	:	Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Ezetimibe / Rosuvastatin Formulation

Version 3.0 Revision Date: 06.04.2024 SDS Number: 3177580-00014 Date of last issue: 30.09.2023
Date of first issue: 18.09.2018

Components:**Ezetimibe:**

Species : Rabbit
Result : No eye irritation

Sodium n-dodecyl sulfate:

Species : Rabbit
Result : Irreversible effects on the eye
Method : OECD Test Guideline 405

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Ezetimibe:**

Test Type : Maximisation Test
Species : Guinea pig
Result : negative

Sodium n-dodecyl sulfate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative
Remarks : Based on data from similar materials

Magnesium stearate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Components:**Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative
Genotoxicity in vivo	:	Test Type: In vitro mammalian cell gene mutation test
		Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
		Species: Mouse
		Application Route: Ingestion
		Result: negative

Ezetimibe:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Metabolic activation: with and without metabolic activation
		Result: negative
Genotoxicity in vivo	:	Test Type: Chromosomal aberration
		Test system: Human lymphocytes
		Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test
		Species: Mouse
		Cell type: Bone marrow
		Application Route: Oral
		Result: negative

Rosuvastatin:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Test system: Escherichia coli
		Result: negative
Genotoxicity in vivo	:	Test Type: Chromosomal aberration
		Test system: Chinese hamster lung cells
		Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test
		Species: Mouse
		Cell type: Bone marrow
		Application Route: Ingestion
		Result: negative

Sodium n-dodecyl sulfate:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Method: OECD Test Guideline 471
		Result: negative

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Genotoxicity in vivo	:	Test Type: In vitro mammalian cell gene mutation test Result: negative
	:	Test Type: Rodent dominant lethal test (germ cell) (in vivo) Species: Mouse Application Route: Ingestion Result: negative

Magnesium stearate:

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials
		Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials
		Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials

Carcinogenicity

May cause cancer.

Components:**Cellulose:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	72 weeks
Result	:	negative

Ezetimibe:

Species	:	Rat, female
Application Route	:	oral (feed)
Exposure time	:	104 weeks
Result	:	negative

Species	:	Rat, male
Application Route	:	oral (feed)
Exposure time	:	104 weeks
Result	:	negative

Species	:	Mouse
Application Route	:	oral (feed)
Exposure time	:	104 weeks
Result	:	negative

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Rosuvastatin:

Species	: Rat
Application Route	: Oral
Exposure time	: 104 weeks
LOAEL	: 80 mg/kg body weight
Result	: positive
Symptoms	: Tumour
Target Organs	: Uterus (including cervix)

Species	: Mouse
Application Route	: Oral
Exposure time	: 107 weeks
LOAEL	: 200 mg/kg body weight
Result	: positive
Symptoms	: liver adenoma, carcinoma
Target Organs	: Liver

Sodium n-dodecyl sulfate:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 2 Years
Method	: OECD Test Guideline 453
Result	: negative
Remarks	: Based on data from similar materials

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:**Cellulose:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

Ezetimibe:

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, male and female Fertility: NOAEL: > 1,000 mg/kg body weight Result: No effects on fertility, No fetotoxicity
Effects on foetal development	: Test Type: Development Species: Rat Application Route: Oral

Ezetimibe / Rosuvastatin Formulation

Version 3.0 Revision Date: 06.04.2024 SDS Number: 3177580-00014 Date of last issue: 30.09.2023
Date of first issue: 18.09.2018

Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects

Rosuvastatin:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 50 mg/kg body weight

Test Type: Fertility
Species: Monkey
Application Route: Oral
Fertility: LOAEL: 30 mg/kg body weight
Result: Effects on male and female reproductive organs.

Effects on foetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 50 mg/kg body weight
Result: foetal mortality

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 3 mg/kg body weight
Result: foetal mortality, Maternal toxicity observed.

Reproductive toxicity - Assessment : May damage fertility. May damage the unborn child.

Sodium n-dodecyl sulfate:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Magnesium stearate:

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Effects on fertility	:	Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials

STOT - single exposure

May cause damage to organs (Liver, Kidney, muscle) if swallowed.

Components:**Rosuvastatin:**

Exposure routes	:	Oral
Target Organs	:	Liver, Kidney, muscle
Assessment	:	Causes damage to organs.

STOT - repeated exposure

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Components:**Rosuvastatin:**

Exposure routes	:	Oral
Target Organs	:	Eye
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Cellulose:**

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

Ezetimibe:

Species	:	Dog
NOAEL	:	1,000 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Remarks	:	No significant adverse effects were reported

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Species	: Rat
NOAEL	: 1,500 mg/kg
Application Route	: Oral
Exposure time	: 90 d
Remarks	: No significant adverse effects were reported

Species	: Mouse
NOAEL	: 500 mg/kg
Application Route	: Oral
Exposure time	: 90 d
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 300 mg/kg
Application Route	: Oral
Exposure time	: 1 yr
Remarks	: No significant adverse effects were reported

Rosuvastatin:

Species	: Dog
LOAEL	: 90 mg/kg
Application Route	: Oral
Exposure time	: 24 Days
Target Organs	: Brain
Symptoms	: Oedema, Blood disorders, Necrosis
Remarks	: Based on data from similar materials

Species	: Dog
LOAEL	: 6 mg/kg
Application Route	: Oral
Exposure time	: 52 Weeks
Target Organs	: Cornea
Symptoms	: Corneal opacity
Remarks	: Based on data from similar materials

Species	: Dog
LOAEL	: 30 mg/kg
Application Route	: Oral
Exposure time	: 12 Weeks
Target Organs	: Eye
Symptoms	: Eye disease
Remarks	: Based on data from similar materials

Species	: Dog
LOAEL	: 90 mg/kg
Application Route	: Oral
Exposure time	: 4 Weeks
Target Organs	: eye - retina
Symptoms	: Eye disease
Remarks	: Based on data from similar materials

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Sodium n-dodecyl sulfate:

Species	: Rat
NOAEL	: 488 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

Magnesium stearate:

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:**Ezetimibe:**

|| Not applicable

Experience with human exposure**Components:****Ezetimibe:**

Ingestion	: Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain
-----------	--

Rosuvastatin:

Ingestion	: Target Organs: Kidney Symptoms: kidney toxicity Remarks: Based on Human Evidence Target Organs: muscle Symptoms: musculoskeletal pain Remarks: Based on Human Evidence Target Organs: Liver Symptoms: liver function change Remarks: Based on Human Evidence
-----------	--

Section 12: Ecological information**Toxicity****Components:****Cellulose:**

Toxicity to fish	: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h
------------------	---

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Remarks: Based on data from similar materials

Ezetimibe:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 4 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l Exposure time: 33 d Method: OECD Test Guideline 210
		NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.282 mg/l Exposure time: 21 d Remarks: No toxicity at the limit of solubility
M-Factor (Chronic aquatic toxicity)	:	1
Toxicity to microorganisms	:	EC50: > 4.4 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
		NOEC: 4.4 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility

Ezetimibe / Rosuvastatin Formulation

Version 3.0 Revision Date: 06.04.2024 SDS Number: 3177580-00014 Date of last issue: 30.09.2023
 Date of first issue: 18.09.2018

Rosuvastatin:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l Exposure time: 96 hrs Method: FDA 4.11
		LC50 (Lepomis macrochirus (Bluegill sunfish)): > 1,000 mg/l Exposure time: 96 hrs Method: FDA 4.11
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 63 mg/l Exposure time: 48 hrs Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Microcystis aeruginosa (blue-green algae)): > 640 mg/l Exposure time: 96 hrs Method: FDA 4.01
		NOEC (Microcystis aeruginosa (blue-green algae)): 330 mg/l Exposure time: 96 hrs Method: FDA 4.01
		EC50 (Pseudokirchneriella subcapitata (green algae)): > 800 mg/l Exposure time: 96 hrs Method: FDA 4.01
		NOEC (Pseudokirchneriella subcapitata (green algae)): 350 mg/l Exposure time: 96 hrs Method: FDA 4.01
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 1 mg/l Exposure time: 32 Days Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.018 mg/l Exposure time: 21 Days Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	:	1
Toxicity to microorganisms	:	EC50: > 100 mg/l Exposure time: 3 hrs Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC: 100 mg/l Exposure time: 3 hrs Test Type: Respiration inhibition Method: OECD Test Guideline 209

Sodium n-dodecyl sulfate:

Ezetimibe / Rosuvastatin Formulation

Version 3.0 Revision Date: 06.04.2024 SDS Number: 3177580-00014 Date of last issue: 30.09.2023
Date of first issue: 18.09.2018

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 29 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Ceriodaphnia dubia (water flea)): 5.55 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l Exposure time: 72 h NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l Exposure time: 72 h
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): >= 1.357 mg/l Exposure time: 42 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Ceriodaphnia dubia (water flea)): 0.88 mg/l Exposure time: 7 d
Toxicity to microorganisms	:	EC50: 135 mg/l Exposure time: 3 h

Magnesium stearate:

Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Ezetimibe:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 6.8 %
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)
Method: OECD Test Guideline 111

Rosuvastatin:

Biodegradability : Biodegradation: < 10 %
Exposure time: 28 Days
Method: OECD Test Guideline 301F
Remarks: Not inherently biodegradable.

Stability in water : Hydrolysis: < 10 %(5 Days)

Sodium n-dodecyl sulfate:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 95 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 173
Exposure time: 97 d
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Rosuvastatin:

Partition coefficient: n-octanol/water : log Pow: 0.3

Sodium n-dodecyl sulfate:

Partition coefficient: n-octanol/water : log Pow: 0.83

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil**Components:****Ezetimibe:**

Distribution among environmental compartments : log Koc: 4.35
Method: OECD Test Guideline 106

Rosuvastatin:

Distribution among environmental compartments : log Koc: 2.15
Method: FDA 3.08

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number : UN 3077

UN proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Ezetimibe, Rosuvastatin)

Transport hazard class(es) : 9

Packing group : III

Labels : 9

Environmental hazards : yes

IATA-DGR

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

UN/ID No. : UN 3077
 UN proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Rosuvastatin)
 Transport hazard class(es) : 9
 Packing group : III
 Labels : Miscellaneous
 Packing instruction (cargo aircraft) : 956
 Packing instruction (passenger aircraft) : 956
 Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Rosuvastatin)
 Transport hazard class(es) : 9
 Packing group : III
 Labels : 9
 EmS Code : F-A, S-F
 Marine pollutant : yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Section 15: Regulatory information**Safety, health and environmental regulations specific for the product in question**

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable
 Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable
 Regulations

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

Section 16: Other information

Revision Date : 06.04.2024

Further informationSources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviationsACGIH : USA. ACGIH Threshold Limit Values (TLV)
SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.ACGIH / TWA : 8-hour, time-weighted average
SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recom-

SAFETY DATA SHEET



Ezetimibe / Rosuvastatin Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	3177580-00014	Date of first issue: 18.09.2018

recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN